Hydrogen-producing milk to prevent reduction in tear stability in persons using visual display terminals.
Motoko Kawashima, Saki Tsuno, Mitsuharu Matsumoto, Kazuo Tsubota · The ocular surface · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 118 participants with mild-to-moderate dry eye symptoms, a significant decline in fTBUT was observed in the placebo group (p = 0.04), but not the H₂-producing group (p = 0.26). These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence oxidative-stress regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 118 participants with mild-to-moderate dry eye symptoms. A significant decline in fTBUT was observed in the placebo group (p = 0.04), but not the H₂-producing group (p = 0.26).
What the Researchers Studied
The researchers studied 118 participants with mild-to-moderate dry eye symptoms. The study used a randomized, double-blind, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Breath H₂ concentration, fluorescein tear film breakup time (fTBUT), Schirmer's test, 8-OHdG concentration in tears, reported ocular symptoms using the dry eye-related QOL score questionnaire, and the visual analogue scale were assessed at weeks 0 and 3. A significant decline in fTBUT was observed in the placebo group (p = 0.04), but not the H₂-producing group (p = 0.26). The authors concluded that H₂-producing milk appeared to retard the decline in tear stability and may prevent short fTBUT-type dry eye by decreasing oxidative stress in the lacrimal functional unit.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence oxidative-stress regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 118 participants with mild-to-moderate dry eye symptoms. The reported sample size was 54. The study used a randomized, double-blind, placebo-controlled human clinical trial.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.